Publication | Closed Access

Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure

Conivaptan HydrochlorideHeart FailureCardiovascular DiseaseMedicinePhysiologyCardiovascular PharmacologyPharmacotherapyVasopressin V1aCardiovascular PharmacodynamicsAnesthesiaPharmacologyCardiologyDiastolic FunctionV2 Receptor Antagonist